AU2001257220A1 - Antisense modulation of inhibitor of dna binding-1 expression - Google Patents
Antisense modulation of inhibitor of dna binding-1 expressionInfo
- Publication number
- AU2001257220A1 AU2001257220A1 AU2001257220A AU5722001A AU2001257220A1 AU 2001257220 A1 AU2001257220 A1 AU 2001257220A1 AU 2001257220 A AU2001257220 A AU 2001257220A AU 5722001 A AU5722001 A AU 5722001A AU 2001257220 A1 AU2001257220 A1 AU 2001257220A1
- Authority
- AU
- Australia
- Prior art keywords
- inhibitor
- expression
- dna binding
- antisense modulation
- antisense
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09561497 | 2000-04-28 | ||
US09/561,497 US6372433B1 (en) | 2000-04-28 | 2000-04-28 | Antisense modulation of inhibitor of DNA binding-1 expression |
PCT/US2001/013209 WO2001083513A2 (en) | 2000-04-28 | 2001-04-25 | Antisense modulation of inhibitor of dna binding-1 expression |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2001257220A1 true AU2001257220A1 (en) | 2001-11-12 |
Family
ID=24242220
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001257220A Abandoned AU2001257220A1 (en) | 2000-04-28 | 2001-04-25 | Antisense modulation of inhibitor of dna binding-1 expression |
Country Status (5)
Country | Link |
---|---|
US (1) | US6372433B1 (en) |
EP (1) | EP1292605A2 (en) |
JP (1) | JP2003531630A (en) |
AU (1) | AU2001257220A1 (en) |
WO (1) | WO2001083513A2 (en) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1326996A4 (en) * | 2000-09-14 | 2005-08-24 | Univ California | Id-1 and id-2 genes and products as diagnostic and prognostic markers and therapeutic targets for treatment of breast cancer and other types of carcinoma |
US20030166282A1 (en) * | 2002-02-01 | 2003-09-04 | David Brown | High potency siRNAS for reducing the expression of target genes |
US20060009409A1 (en) | 2002-02-01 | 2006-01-12 | Woolf Tod M | Double-stranded oligonucleotides |
EP2221377B2 (en) | 2002-02-01 | 2017-05-17 | Life Technologies Corporation | Oligonucleotide compositions with enhanced efficiency |
US20040248094A1 (en) * | 2002-06-12 | 2004-12-09 | Ford Lance P. | Methods and compositions relating to labeled RNA molecules that reduce gene expression |
US20100075423A1 (en) * | 2002-06-12 | 2010-03-25 | Life Technologies Corporation | Methods and compositions relating to polypeptides with rnase iii domains that mediate rna interference |
AU2003276666A1 (en) * | 2002-06-12 | 2003-12-31 | Ambion, Inc. | Methods and compositions relating to polypeptides with rnase iii domains that mediate rna interference |
US20040029275A1 (en) * | 2002-08-10 | 2004-02-12 | David Brown | Methods and compositions for reducing target gene expression using cocktails of siRNAs or constructs expressing siRNAs |
US20060142228A1 (en) * | 2004-12-23 | 2006-06-29 | Ambion, Inc. | Methods and compositions concerning siRNA's as mediators of RNA interference |
US8895701B2 (en) * | 2008-01-05 | 2014-11-25 | Sloan-Kettering Institute For Cancer Research | Peptide-conjugated oligonucleotide therapeutic and method of making and using same |
JP5420946B2 (en) * | 2009-03-23 | 2014-02-19 | 富士フイルム株式会社 | Minoxidil aqueous composition containing bile acids |
JP6902869B2 (en) * | 2014-03-19 | 2021-07-14 | アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. | Composition for regulating the expression of ataxin 2 |
AR115847A1 (en) | 2018-07-25 | 2021-03-03 | Ionis Pharmaceuticals Inc | COMPOUNDS AND METHODS TO REDUCE THE EXPRESSION OF ATXN2 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4032434B2 (en) * | 1992-11-13 | 2008-01-16 | 住友電気工業株式会社 | Human Id gene |
US5801154A (en) * | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
-
2000
- 2000-04-28 US US09/561,497 patent/US6372433B1/en not_active Expired - Lifetime
-
2001
- 2001-04-25 EP EP01930712A patent/EP1292605A2/en not_active Withdrawn
- 2001-04-25 AU AU2001257220A patent/AU2001257220A1/en not_active Abandoned
- 2001-04-25 WO PCT/US2001/013209 patent/WO2001083513A2/en not_active Application Discontinuation
- 2001-04-25 JP JP2001580937A patent/JP2003531630A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2003531630A (en) | 2003-10-28 |
US6372433B1 (en) | 2002-04-16 |
EP1292605A2 (en) | 2003-03-19 |
WO2001083513A2 (en) | 2001-11-08 |
WO2001083513A3 (en) | 2002-05-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2001289085A1 (en) | Antisense modulation of flip-c expression | |
AU2002227435A1 (en) | Antisense modulation of calreticulin expression | |
AU2001294926A1 (en) | Antisense modulation of smad6 expression | |
AU2001229447A1 (en) | Antisense modulation of smad7 expression | |
AU2001229493A1 (en) | Antisense modulation of mekk2 expression | |
AU2001277054A1 (en) | Antisense modulation of lysophospholipase i expression | |
AU2002309819A1 (en) | Antisense modulation of PTP1B expression | |
AU2001278077A1 (en) | Antisense modulation of ptp1b expression | |
AU2002350228A1 (en) | Antisense modulation of myd88 expression | |
AU2001263171A1 (en) | Antisense modulation of tert expression | |
AU2001239971A1 (en) | Antisense modulation of parp expression | |
AU2001277003A1 (en) | Antisense inhibition of her-3 expression | |
AU2001257220A1 (en) | Antisense modulation of inhibitor of dna binding-1 expression | |
AU2001227847A1 (en) | Antisense modulation of pepck-cytosolic expression | |
AU2002366788A1 (en) | Antisense modulation of ship-1 expression | |
AU2002318139A1 (en) | Antisense modulation of src-c expression | |
AU2001283443A1 (en) | Antisense modulation of hpk/gck-like kinase expression | |
AU2002230869A1 (en) | Antisense modulation of hepsin expression | |
AU2002226064A1 (en) | Antisense modulation of talin expression | |
AU2002357102A1 (en) | Antisense modulation of cd36l1 expression | |
AU2001287136A1 (en) | Antisense modulation of glioma-associated oncogene-1 expression | |
AU2002214038A1 (en) | Inhibitors of transglutaminases | |
AU2001296731A1 (en) | Antisense modulation of bcas1 expression | |
AU2001296412A1 (en) | Antisense modulation of mekk4 expression | |
AU2001234461A1 (en) | Antisense modulation of daxx expression |